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Abstract 
Worldwide, metastasis is the leading cause of more than 90% of cancer-related deaths. Currently, no specific therapies 
effectively impede metastasis. Metastatic processes are controlled by complex regulatory networks and transcrip-
tional hierarchy. Corepressor metastasis-associated protein 3 (MTA3) has been confirmed as a novel component of 
nucleosome remodeling and histone deacetylation (NuRD). Increasing evidence supports the theory that, in the 
recruitment of transcription factors, coregulators function as master regulators rather than passive passengers. As 
a master regulator, MTA3 governs the target selection for NuRD and functions as a transcriptional repressor. MTA3 
dysregulation is associated with tumor progression, invasion, and metastasis in various cancers. MTA3 is also a key 
regulator of E-cadherin expression and epithelial-to-mesenchymal transition. Elucidating the functions of MTA3 might 
help to find additional therapeutic approaches for targeting components of NuRD.
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Background
Cancer begins as a local disease and progresses to meta-
static diseases in other organs. The most devastating can-
cer process is metastasis, which accounts for more than 
90% of cancer-related deaths worldwide [1]. Metastasis 
requires malignant primary tumor cells to penetrate the 
walls of lymphatic and/or blood vessels, circulate through 
the blood or lymph stream to distant organs, and colo-
nize there to seed micrometastases. These micrometas-
tases dedifferentiate through aberrant activation of 
epithelial-to-mesenchymal transition (EMT) to form a 
metastatic tumor [2–4]. EMT strongly enhances cancer 
cell motility and dissemination by dictating the interac-
tions of cancer cells with the extracellular matrix (ECM) 
and neighboring stromal cells. EMT involves in the dys-
regulation of cell adhesion molecules (CAMs) such as 
integrins, immunoglobulin superfamily, and cadherins, 
all of which are implicated in metastasis [5–7]. Thus, 
activation of EMT is important for cancer cell dissemi-
nation and metastasis. EMT is a highly conserved cellu-
lar process that transforms polarized, immotile epithelial 
cells to migratory mesenchymal cells with stem cell-like 
properties. It is orchestrated by a group of transcription 
factors such as Snail (or SNAI1), Slug, Twist, and Zinc 
finger E-box-binding homeobox (ZEB) families [8, 9]. 
Metastasis-associated protein 3 (MTA3) has been proved 
as a novel component of the nucleosome remodeling and 
histone deacetylation (NuRD) transcriptional repression 
complex. As a transcriptional corepressor, MTA3 directly 
or indirectly regulates the activity of EMT-associated 
genes such as Snail and E-cadherin. A decrease of MTA3 
expression leads to the up-regulation of Snail and triggers 
the process of EMT by repressing E-cadherin, thereby 
causing a loss of cell-to-cell adhesion and promoting can-
cer invasion and metastasis. Underexpression of MTA3 
has been observed in a diverse array of human tumors 
[10–16]. MTA3, as a master regulator, may regulate the 
EMT-relevant metastasis by modulating the expression 
of the crucial proteins Snail and E-cadherin.
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Many roads to metastasis: EMT and beyond
Cancer metastasis is an intricate multistep process 
involving the detachment of cancer cells from the pri-
mary tumor, the penetration through adjacent tissue to 
the vasculature, and location on the distant organs where 
they survive and proliferate and therefore generate meta-
static tumor [17–20]. Migration of cancer cells is initiated 
by their detachment from the ECM, then the genes that 
are necessary for differentiation, proliferation, and apop-
tosis are activated. To initiate migration, the metastatic 
cancer cells must undergo EMT by changing their cellu-
lar characteristics and down-regulating the expression of 
receptors involved in cell-to-cell adhesion. Then the cell 
motility is increased by down-regulating cell adhesion 
molecules, degrading cell-to-cell junctions, and activat-
ing proteases, finally releasing cancer cells from the ECM 
[9, 21, 22]. The epigenetic pattern that promotes such 
metastatic changes varies for different types of cancer 
cells, and each pattern has its unique clinical significance. 
The migration of cancer cells generally occurs via two 
different types of movement: (1) single-cell migration, 
involving amoeboid and mesenchymal movement, and 
(2) collective migration, involving the movement of cells 
in the form of sheets, strands, clusters, or ducts rather 
than individually (Fig.  1). However, two types of migra-
tions interact intensively during cancer metastasis.
Single‑cell invasion or individual‑cell migration
Single-cell tumor invasion or migration is characterized 
by low association in the migration pattern between cells, 
that is, when released from ECM, a cell has no interac-
tion with its neighboring cells [23]. Single-cell migration 
occurs by amoeboid or mesenchymal movement [24–26].
Amoeboid cell migration
The amoeboid mechanism is the most primitive and effi-
cient mode of single-cell migration from tumors such as 
lobular breast cancer [27], epithelial prostate cancer [28], 
leukemia [29], and melanoma [30]. This type of invasion 
is characterized by absent or minimal focal adhesion due 
to weak interaction between cells and the substratum 
matrix as well as absent or minimal proteolysis at the 
site of cell–matrix interactions, since the ECM destroy-
ing proteolytic enzymes are not expressed [25, 31–33]. 
All these properties determine that amoeboid cells have 
characteristic fast deformability and the ability to pen-
etrate in squeezed form through small spaces of ECM 
[26, 34, 35]. The cell migration and relocation is accom-
plished through “bleb-like” pseudopodial protrusions 
of the cell membrane developed by alternate cycles of 
expansion and contraction of the cell body. These pseu-
dopodial protrusions through their chemoreceptors 
sense the microenvironment and help the cells to bypass 
various obstacles and find the most suitable route to 
squeeze through narrow gaps in the ECM. Changes in the 
cell shape during amoeboid movement are generated by 
the actin cytoskeleton which is controlled by a group of 
molecules, including small GTPase, Rac, RhoA, and its 
effector ROCK kinase, that are required to reorganize the 
actin cytoskeleton during cell migration [24–26, 32, 36].
Mesenchymal cell migration
Compared with the amoeboid cell migration, mesen-
chymal cell migration is accomplished by more com-
plex processes involving larger numbers of biomolecular 
interactions; this invasion is characterized by a spin-
dle-shaped elongated cell body with long protrusions. 
Mesenchymal cell invasion has been detected during 
the development of breast and prostate cancers, lung 
Fig. 1 Models and transitions of tumor cell metastasis. a Migration 
of whole groups of cancer cells; b migration of individual cancer cell. 
EMT epithelial-mesenchymal transition, MAT mesenchymal-amoeboid 
transition, AMT amoeboid-mesenchymal transition, ZEB1/2 zinc finger 
E-box-binding homeobox 1 and 2
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carcinoma, melanoma, fibrosarcoma, glioblastoma, and 
many other cancers [26, 37]. During this type of migra-
tion, malignant cells gain an elongated spindle shape 
which resembles fibroblasts by losing their epithelial 
polarity; thus, this type of migration is also called “fibro-
blast-like” migration [24, 26, 38, 39].
The mesenchymal migration of cancer cells occurs 
through multiple sequential steps: (1) on one of the cell 
poles, the contractions of the actin cytoskeleton pro-
duces a protrusion called a lamellipodia or a filopodia 
under the control of small GTPases, Rac1, Cdc42, and 
β1 family integrins; (2) focal adhesion is generated at 
the site of contact between the cell and ECM involving 
β1 and β3 integrins; (3) assembly of focal contacts occurs 
due to integrin-mediated interactions and activation of 
matrix metalloproteinases, cathepsins, and serine and 
threonine proteolytic enzymes at the cell–matrix inter-
face destructing and reorganizing the surrounding ECM; 
(4) myosin II-mediated change in the actin cytoskeleton 
polarization leads to the cell body contractions; and (5) 
the newly formed defects in the matrix structure pull the 
trailing edge toward the direction of movement [24, 26, 
32, 40, 41].
Collective cell migration
Collective cell migration is pivotal in tissue remodeling, 
wound healing, tissue renewal in adults, and cancer 
metastasis. In contrast to single-cell migration, the cells 
remain in constant intercellular communication during 
collective cell migration for the coordination of move-
ment. Collective cell migration has been observed in the 
development and progression of breast cancer [42, 43], 
endometrial cancer [44], colorectal cancer [45, 46], mela-
noma [47], and oral squamous cell carcinomas [48].
Collective cell migration can be observed in two-
dimensional (2D) sheet migration across a tissue surface 
or in multicellular strands or groups moving through a 
three-dimensional (3D) tissue scaffold. 2D sheets move 
as monolayers across tissues or along tissue clefts to form 
a single-layer epithelium or, after subsequent prolifera-
tion and thickening, form a multilayer epithelium. The 
multicellular 3D strands have a distinct basal and lateral 
polarization constituting an inner lumen, and therefore 
have a tubular structure, for instance, in morphogenic 
duct and gland formation or vascular sprouting during 
angiogenesis, or they can move as a poorly organized 
strand-like mass, such as in invasive cancer. Alternatively, 
isolated groups or clusters of cells can migrate through 
tissue if they detach from their origins; for example, met-
astatic cancer cell clusters penetrate the stromal tissues 
[44, 49, 50].
The collective cell migration involves two types of cells: 
the “leader” cells forming the leading edge that generates 
adhesion and traction towards the tissue substrate and 
the “follower” cells that are located behind them. Leader 
cells acquire the mesenchymal phenotype with less dis-
tinct ordering and structural organization; however, 
toward the trailing edge the follower cells display an api-
cal formation of tight junctions before being deposited 
and tend to form more tightly packed rosette-like tubu-
lar cluster of cells. These leader cells direct multicellular 
aggregates through degradation of the ECM components 
at the invasion front, and the cells of the inner and trail-
ing edge are dragged forward. Since they play the domi-
nant roles in the movement of cell collectives, the leader 
cells are of great significance in relation to EMT. Collec-
tive migration is used by epithelial cancer cells as well as 
by mesenchymal cancer cells [47, 51–53].
EMT
EMT is a type of migrating movement that belongs to 
collective-individual transition. EMT is considered one 
of the crucial initiative steps for cancer cell metastasis, 
which enhances the migratory capacity of cancer cells by 
promoting epithelial cells to lose their polarity and inter-
cellular adhesion to acquire mesenchymal features [3]. 
During the EMT process, epithelial cells acquire a fibro-
blastic motile phenotype by losing their cell–cell adhe-
sion properties and apical-basal polarity. In solid tumors, 
migrating tumor cells are produced by EMT. In turn, 
migrating tumor cells that have undergone EMT reach 
and reside in metastatic organs and are able to form 
tumor multicellular complexes by regaining an epithelial 
phenotype called mesenchymal-to-epithelial transition 
(MET) [54, 55]. Hallmarks of EMT are the down-reg-
ulation of E-cadherin and up-regulation of vimentin, 
which are tightly controlled by multiple signaling cas-
cades. Transforming growth factor-β (TGF-β) plays most 
prominent role in promoting the conversion of epithelial 
to mesenchymal characteristics by transcriptional and 
post-transcriptional regulation of a distinct set of tran-
scription factors [56–61]. A variety of transcriptional fac-
tors such as the zinc finger Snail homologues (Snail1 and 
Snail2/Slug) and different basic helix-loop-helix factors 
(Twist, ZEB1, and ZEB2), which are capable of triggering 
cellular reprogramming, have been demonstrated to pro-
mote EMT through the coordinated modulation of EMT-
related genes [62–66].
Multiple extracellular stimuli, including epidermal 
growth factor (EGF), hepatocyte growth factor (HGF), 
Notch, Wnt, TGF-β, and platelet-derived growth factor 
(PDGF), orchestrate the EMT-related process by inte-
grated networks of signal transduction pathways and 
transcription factors. Transcription factors such as Snail, 
Twist, ZEB, and histone deacetylase (HDAC), which are 
capable of triggering cellular reprogramming, are the key 
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strength of EMT. Since the expression of these EMT-rel-
evant transcription factors is tightly orchestrated by tran-
scriptional hierarchy, coregulators play a master role in 
the expression of transcription factors that subsequently 
regulate EMT and metastasis [67–69].
MicroRNAs (miRNAs) also crucially regulate EMT 
and have been found to be dysregulated in diverse array 
of human cancers [70]. miRNAs play an important role 
in the control of cell growth, differentiation, maturation, 
and apoptosis, which are critical for the development and 
progression of cancer [71]. miRNAs are also involved in 
the regulation of multiple signaling pathways in EMT [71, 
72]. miR-21, an identified “oncomiR,” has been implicated 
in the promotion of EMT [73]. Inhibition of miR-21 was 
sufficient to inhibit EMT and stemness [74]. miR-506 in 
EMT inhibition has also been demonstrated in several 
other cancer types [71, 75, 76], indicating that miR-506 
functions as a tumor suppressor in a wide spectrum of 
cancers. Other well-known miRNAs regulating EMT are 
miR-101, miR-200c, and miR-141 [71].
Master coregulators: metastasis promoters 
and suppressors
Transcriptional coregulators are a large family of proteins 
that either activate (coactivator) or repress (corepressor) 
the transcription of specific genes by interacting with 
transcription factors. These proteins can be recruited 
to the enhancer or promoter regions of target genes 
through interaction with transcription factors to medi-
ate their transcriptional potency, even though they do 
not have intrinsic DNA-binding capacity. Transcription 
coregulators regulate the expression of a gene either by 
modifying chromatin structure through covalent modifi-
cation of histones or modifying chromatin conformation 
in an ATP-dependent manner. In contrast to recruitment 
by transcription factors, coregulators are recognized as 
master regulators that coordinately control groups of 
genes at the transcriptional level. Increasing evidence has 
shown that coregulators have more versatile functions in 
elongation, splicing, and further translation.
Coregulators embrace the efficacy and selectivity for 
sub-reactions of transcription and critically influence 
tissue-selective gene functions, including maintenance 
of cell proliferation, differentiation, adhesion, migration, 
and apoptosis. Since each tissue has a specific expression 
profile and concentration of coregulators for maintaining 
its normal homeostasis, any alteration in cellular concen-
tration of coregulators may lead to functional dysregula-
tion of molecular machinery and genetic instability of the 
cell or specific tissue, which cause pathologic complica-
tions such as cancers. In many cancers, coregulators are 
mis-expressed and are hijacked by these cancer cells to 
modulate their sustained proliferation and metastasis.
Emerging evidence indicates that coregulators play 
a regulatory role in EMT and cancer metastasis. In this 
regard, coactivators such as steroid receptor coactivators 
(SRCs, i.e., SRC-1, SRC-2, and SRC-3), proline, glutamate, 
and leucine rich protein 1 (PELP1) [77], peroxisome pro-
liferator-activated receptor γ coactivator-1 (PGC-1) [78], 
and Yes-associated protein (YAP) [79], as well as core-
pressors including metastasis-associated protein family 
(i.e., MTA1, MTA2, and MTA3) [80], nuclear receptor 
corepressor (N-CoR) [81, 82], silencing mediator of reti-
noic acid and thyroid hormone receptor (SMRT) [81], 
switch-independent 3A (Sin3A) [83], C-terminal bind-
ing protein (CtBP) [84], and HDAC3 [85], have been 
reported to regulate tumor cell invasion and metastasis.
Many coregulators are capable of mediating both tumor 
growth and metastasis. The steroid receptor coactivator 
(SRC) family is the major coactivator for nuclear recep-
tor (NR)-dependent transcription [86]. The SRC family 
consists of three members: SRC-1, SRC-2, and SRC-3. In 
cancers, both SRC-2 and SRC-3 not only promote tumor 
growth but also mediate metastasis [87, 88]. SRC-3 also 
plays a pivotal role in constitutive androstane receptor 
(CAR) activation and promotes proliferation and drug 
metabolism in the liver [89]. Interestingly, data derived 
from studies on breast cancer showed that SRC-1, the 
first discovered and cloned coactivator, is exclusively 
responsible for promoting metastasis without accelerat-
ing tumor growth [90]. SRC-1 plays a vital role in cancer 
cell invasion through multiple mechanisms by modulat-
ing twist, polyoma enhancer activator 3 (PEA3), Snail, 
and Smad interacting protein 1 (SIP1) [91, 92]. Thus, it 
is possible that SCR-1 may fall into category of proteins 
that are defined as potent metastasis suppressors.
MTA proteins: regulators of metastasis
Metastasis-associated protein (MTA) family is an emerg-
ing family of novel transcriptional coregulators that are 
specifically relevant to metastasis regulation, which 
comprises six members—MTA1, MTA1s, MTA-ZG29p, 
MTA2, MTA3, and MTA3L—that are separately encoded. 
MTA family members generally form independent NuRD 
complexes that repress transcription by recruiting his-
tone deacetylases on different target genes. MTAs are 
the key components of the NuRD complex, which show 
a crucial role in cancer cell invasion and metastasis, 
associating with a variety of cancer-related factors such 
as Snail, E-cadherin, and signal transducer and activator 
of transcriptions (STATs) [80]. Furthermore, MTAs are 
also regulated by various factors [10, 80, 93, 94] (Fig. 2). 
The absence of estrogen receptor or MTA3 leads to aber-
rant up-regulation of Snail, resulting in loss of E-cad-
herin expression. MTA3 protein is required in normal 
development for sustaining the controlled cell growth 
Page 5 of 11Du et al. Chin J Cancer  (2017) 36:28 
Fig. 2 Upstream regulators and downstream effectors of metastasis-associated proteins (MTAs) in human cancers. Upstream regulators that directly 
or indirectly up-regulate or down-regulate MTA1 (a), MTA2 (b), and MTA3 (c) are listed on the left side, whereas downstream effectors that are 
directly or indirectly regulated by MTAs are listed on the corresponding right side. VEGF vascular endothelial growth factor, AKT protein kinase, LPS 
lipopolysaccharide, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, TGF-β1 transforming growth factor beta 1, HBx hepatitis 
B viral protein, EIF5A2 eukaryotic translation initiation factor 5A-2, ARF alternative reading frame, COP1 coat protein 1, 15-LOX-1 15-lipoxygenase-1, 
SUMO2 small ubiquitin-related modifier 2, CXCL1 chemokine (C-X-C motif ) ligand 1, BCAS3 breast carcinoma-amplified sequence 3, TG2 transglu-
taminase 2, Pax-5 paired box protein 5, STAT3 signal transducer and activator of transcription 3, HIF-α hypoxia-inducible factor-α, MMP-9 matrix 
metallopeptidase 9, miR-125b microRNA-125b, ERα estrogen receptor alpha, BRCA1 breast cancer 1, NR4A1 nuclear receptor subfamily 4 group A 
member 1, Gαi2 Gi alpha subunit 2, PTEN phosphatase and tensin homolog, SMAD7 mothers against decapentaplegic homolog 7, Sp1 specificity 
protein 1, p120ctn p120 catenin, EGFR epidermal growth factor receptor, GDIα GDP dissociation inhibitor alpha, hBD-3 human β-defensin 3, IL-11 
interleukin-11, PELP1 proline, glutamic acid, leucine-rich protein 1, MTA1 s metastasis-associated protein 1s, PRMD1 PR domain containing 1, with 
ZNF domain, ZEB2 zinc finger E-box-binding homeobox 2
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and homeostasis and, in cancers, to combat the spread 
of cancers through EMT and metastasis [95]. Interest-
ingly, MTA protein family members have been identi-
fied as transcription corepressors; however, they may 
form functionally specialized NuRD complex and then 
display varied roles in cancer initiation, progression, and 
metastasis. MTA1 is the founder of the MTA family and 
is found to be overexpressed in breast cancer [80], caus-
ing increased EMT, migration, and metastasis; however, 
there are remarkable differences among MTA3, MTA1, 
and MTA 2.
MTA3 was identified as a component of Mi2/NuRD 
complex and transcriptional corepressor, which is 
dependent on estrogen and negatively regulate gene 
expression in breast cancer cells [21]. In response to 
estrogen, a distinct MTA3-Mi2/NuRD transcriptional 
corepressor complex is formed, which contains histone 
deacetylase and has ATP-dependent chromatin remod-
eling functions [10]. This complex modulates the expres-
sion of E-cadherin by inhibiting expression of Snail [10], 
which further blocks EMT. Since MTA3 is a transcrip-
tional target of estrogen receptor-α (ERα), the function 
of MTA3 is linked to the ERα pathway. In the presence 
of ligand, ERα directly binds to the MTA3 promoter at 
the half-estrogen response element (ERE)/Sp1-binding 
site and stimulates MTA3 transcription [96, 97]. Since 
both MTA1 and MTA1  s negatively regulate ERα func-
tion and MTA3 is an estrogen-regulated gene, any prob-
able up-regulation of MTA1 or MTA1  s may lead to 
decrease of the expression of MTA3. Any regulated 
reduction in the level of MTA3 will lead to up-regulation 
of Snail, enhancement of EMT, and metastasis of breast 
cancer. MTA3 influences the Wnt signaling and directly 
represses Wnt4 transcription [11], which countermands 
Snail activation induced by Wnt [98].
Association of MTA3 with EMT and metastasis 
in cancers
Although MTA3 is involved in multiple cellular activi-
ties in physiological and pathologic processes, MTA3 has 
been extensively studied for its regulation and associa-
tion with EMT and metastasis in cancer (Fig. 3).
Underexpression of MTA3 in cancers
MTA3 was first found to be down-regulated in cancers 
and repress EMT and invasion.
Breast cancer
MTA3 was originally identified as a corepressor that 
inhibits breast cancer cell EMT, invasion, and metasta-
sis [10], and its protein expression is gradually decreased 
during progression in breast cancer tissues [11]. In cul-
tured ER-positive MCF-7 cell lines, depletion of MTA3 
increases expression of Snail, which regulates EMT, and 
in turn reduces E-cadherin expression and improves 
invasive growth [10]. Because MTA3 is a cell type-
specific component of the NuRD complex, and MTA3 
expression depends on estrogen action, MTA3 regulates 
EMT and cancer metastasis of breast cancer via the ER-
MTA3/NuRD/Snail/E-cadherin pathway. Using mouse 
mammary tumor virus polyoma virus middle T (MMTV-
PyV-mT) transgenic mouse model, MTA3 expression was 
compared with that of MTA1 and MTA2 in normal duct, 
premalignant lesions, invasive carcinoma, and meta-
static tumors [11]. The results showed that MTA3 protein 
expression had a positive association with that of E-cad-
herin and cytoplasmic β-catenin and that MTA3 protein 
expression was progressively reduced during breast can-
cer progression [11]. These results proved that MTA3 
exhibits a critical role in EMT and cancer metastasis.
Gastroesophageal junction adenocarcinoma
Gastroesophageal junction (GEJ) adenocarcinoma is a 
malignancy that shows frequent metastasis. In GEJ ade-
nocarcinoma, the components of the MTA3 pathway 
were proved to be of prognostic significance [15]. Down-
regulation of MTA3 mRNA and protein was detected in 
tumor tissues compared with non-tumor tissues; MTA3 
levels were significantly lower in tumor cell lines with 
stronger metastatic potential compared with tumor 
cell lines with less metastatic potential [15]. It was also 
observed that the patients with low MTA3 expression 
had poor prognosis [15]. Furthermore, the malignant 
properties were found to be strongly associated with the 
abnormal expression of MTA3, Snail, and E-cadherin 
[15], suggesting that MTA3 regulates EMT and promotes 
metastasis via repressing Snail expression. These data 
reveal that MTA3 can serve as an independent prognos-
tic factor for patients with GEJ adenocarcinoma.
Glioma, ovarian cancer, and endometrial cancer
MTA3 is underexpressed in glioma [99], ovarian cancer 
[100], and endometrial cancer [101]. MTA3 expression 
was reported to be associated with differentiation [13], 
cancer progression [14], and overall survival rates [14, 
99]. Given that the malignancies such as glioma, ovarian 
cancer, and endometrial cancer have nature of invasive 
and migration, further studies are required to elucidate 
how MTA3 regulates the EMT and metastasis in these 
cancers.
Up‑regulation of MTA3 in cancers
Besides down-regulation, MTA3 was also found to be up-
regulated in cancers [12, 14, 102]. Compared with MTA1 
and MTA2, MTA3 may have more complex functions in 
cancer progression.
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Non‑small cell lung cancer
Non-small cell lung cancer (NSCLC) represents approx-
imately 85% of lung cancers; approximately 40% of 
NSCLC patients have poor prognosis due to cancer cell 
invasion [103]. It has been observed that MTA3 was over-
expressed in NSCLC tissue, which can serve as a risk fac-
tor for lymph node metastasis [102]. Furthermore, MTA3 
was found to be a target of miR-495, which inhibited pro-
liferation and migration in lung cancer cells [102]. These 
findings suggest that miR-495 could be of great clinical 
importance in targeting MTA3 for regulating lung cancer 
growth and migration.
Metastasis and therapeutic resistance have been 
demonstrated to be the major causes of the failure of 
cancer treatment [104]. A body of evidence has identi-
fied EMT as a key step for facilitating cancer metasta-
sis and radioresistance [105]. For example, liver kinase 
B1 (LKB1)-salt-inducible kinase 1 (SIK1) signaling has 
been shown to suppress EMT [106]. In radioresist-
ant NSCLC cells, LKB1-SIK1 signaling was attenu-
ated; however, radiosensitivity of NSCLC cells was 
increased by re-expression of LKB1 [107]. Since MTA3 
was involved in the regulation of EMT by miR-495 in 
NSCLC cells [102], it is reasonable to speculate that 
MTA3 may also play a role in regulation of therapeutic 
resistance in NSCLC.
Chorionic carcinoma
Human chorionic carcinoma is an aggressive and meta-
static carcinoma. It is well known that MTA3 is involved 
in cancer cell migration by regulating cell adhesion 
proteins. Bruning et  al. [12] recently reported high 
expression of MTA1 and MTA3 in the nuclei of human 
chorionic carcinoma cells, suggesting that high expres-
sion level of MTA proteins might facilitate trophoblast 
cell migration and neoangiogenesis.
Fig. 3 Aberrant expression of MTA3 in a host of human tumor types. NSCLC non-small cell lung cancer, GEJ gastroesophageal junction, NuRD 
nucleosome remodeling and histone deacetylation
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Uterine non‑endometrial cancer
Non-endometrioid carcinoma, a highly malignant form 
of endometrial cancer, has a poor prognosis, mostly due 
to its increased tendency for extra-uterine metastasis 
[108]. In contrast to its underexpression in endometri-
oid carcinomas, MTA3 was found to be overexpressed in 
uterine non-endometrial cancer [14]. MTA3 overexpres-
sion was positively associated with high International 
Federation of Gynecology and Obstetrics (FIGO) surgi-
cal stage, lymph node metastasis, and lymphovascular 
space invasion (LVSI) [14]. Patients with a higher MTA3 
expression were more likely to have shorter progression-
free, cause-specific, and overall survival compared with 
those with a lower MTA3 expression [14]. Interestingly, 
MTA3 can be considered an independent prognostic fac-
tor only for cause-specific survival [14]. These data indi-
cated that elevated MTA3 expression might contribute to 
a more aggressive phenotype in non-endometrial cancer. 
It would be extremely intriguing and important to exam-
ine whether MTA3 expression could serve as a biomarker 
to differentiate endometrioid from non-endometrioid 
carcinomas.
MTA3 regulates many metastasis‑relevant genes
MTA3 in the NuRD complexes was found to target a 
set of genes that may be involved in EMT and metasta-
sis [95]. The first notion about the molecular and bio-
chemical functions of MTA3 was revealed by Fujita et al. 
[10], who reported MTA3 as an estrogen-inducible gene 
product that forms a distinct NuRD complex with strong 
transcription-repressing activity on Snai1 and then up-
regulates E-cadherin, subsequently inhibiting EMT. 
Later, MTA3 was also found to interact with the Wnt4-
containing chromatin in an HDAC-dependent manner, 
thus, repressing Wnt4 transcription [109]. Since a role 
of Wnt signaling for breast cancer metastasis has been 
described [1], it is reasonable to speculate that MTA3 
might inhibit metastasis via suppressing Wnt signaling. 
Lysine-specific demethylase-1 (LSD1) is a physical inte-
gral component of the MTA3/NuRD complex in vivo; the 
LSD1/MTA3/NuRD complex targets TGFβ1, then inhib-
its the invasiveness in  vitro and suppresses metastatic 
potential in  vivo in breast cancer [110]. More recently, 
the MTA3/NuRD complex was reported to be physically 
associated with GATA-binding protein 3 (GATA3) and 
G9A, and the functional GATA3/G9A/NuRD (MTA3) 
complex can inhibit ZEB2 [93]. The authors postulated 
a new mechanism in MTA3-mediated control of EMT 
and cell invasion in breast cancer [93]. Moreover, these 
results suggested that dysregulation of the reciprocal 
feedback between GATA3/G9A/NuRD (MTA3) and 
ZEB2/G9A/NuRD (MTA1) may contribute to breast can-
cer progression.
Summary and future insight
In summary, MTA3 is a decisive modulator for EMT 
and metastasis in cancers. However, our understanding 
of MTA3 mechanism is the tip of the iceberg, and many 
questions still need addressing. For instance, it remains 
to be determined whether MTA3 regulates other meta-
static manners in addition to EMT. Besides transcrip-
tional initiation, coregulators have been found to be 
involved in elongation, splicing, and further translation. 
However, does MTA3 have more functions than tran-
scriptional coregulator? Current evidence shows that 
MTA3 acts in a HDAC-dependent manner. It is unclear 
whether MTA3 could function in the HDAC-independ-
ent pathway. From a translational viewpoint, the associa-
tion between MTA3-mediated signaling, aggressiveness, 
and clinical outcomes has not been fully examined in dif-
ferent cancers.
Cellular activities in cancer metastasis are controlled by 
a hierarchy of different mechanisms. One of such impor-
tant molecular mechanisms is involved in modification at 
transcriptional levels through NuRD-mediated chromo-
somal remodeling. Elucidating functions of MTA3 might 
provide further approaches for targeting components of 
NuRD for therapeutic purposes.
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